Search Results
Your search for ,maY matches 17054 pages
Showing 301 - 350Underlying Mechanisms of Chemoresistance in AML
Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer Discovery. They identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...
Treatment-Resistant Melanoma: Novel Checkpoint Inhibitor Combination
New research published by Phadke et al in the Journal for ImmunoTherapy of Cancer found that adding a third immune-targeting drug to existing therapies may help to shrink tumors in laboratory models of treatment-resistant melanoma. Although immunotherapeutics have improved survival for many...
Can a Mitochondrial Antioxidant Drive Metastasis?
Mounting evidence suggests that the mitochondria may be a driving force behind cancer. A new report points to the mitochondrial metabolite glutathione, highlighting its central role in helping breast cancer cells break away from the primary tumor, travel through the body, and take root in other...
Case 2: Patient With Myelofibrosis and Anemia
This is Part 2 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...
New Report Supports Overhaul of Cancer Drug Dosing
A new study calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the “maximum tolerated dose” (MTD) may be outdated, harmful to patients, and ill-suited for modern cancer therapies. “The Totality of the Evidence: Optimizing Dosage ...
Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma
The addition of the PD-1 inhibitor sintilimab to ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appeared to significantly improve the complete remission rate and showed a trend toward improved progression-free survival in second-line classical Hodgkin lymphoma, according to Yuankai Shi,...
Are Postmastectomy Implant-Based Breast Reconstructions Associated With Lymphomas of the Breast?
The results of a cohort study published in JAMA Network Open revealed an epidemiologic association between postmastectomy implant-based breast reconstruction for any breast tumor and both B- and T-cell non-Hodgkin lymphomas of the breast. According to Kinslow et al, this includes diffuse large...
A Diagnosis of Stage IV Lung Cancer at 18 Has Tested My Faith—and Made It Stronger
The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I began experiencing a persistent cough. The coughing became so unrelenting over the next month, I...
Bridging the Gap: Stronger Primary Care Ties May Improve Cancer Survivorship
Optimal continued care for patients with cancer may require greater involvement from primary care clinicians, according to the results of an observational study published in Current Oncology. The study highlighted certain challenges in cancer care, including patient-centered coordination and...
New Drug-Releasing System Eliminates Bladder Cancer in Over 80% of Patients in a Phase II Trial
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in the phase II SunRISe-1 trial (ClinicalTrials.gov identifier NCT04640623) for individuals with high-risk non–muscle-invasive bladder cancer whose disease had previously resisted treatment. In the majority of cases, the...
Clinically Significant Fatigue and Inflammation in Breast Cancer Survivors
Clinically significant fatigue was associated with increased inflammation in breast cancer survivors, according to study findings published in BMC Women's Health. The study authors also suggested that an increase in inflammatory markers from clinical fatigue could lead to breast cancer recurrence. ...
Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows
The introduction of artificial intelligence (AI) to assist colonoscopies may be linked to a reduction in the ability of endoscopists to detect adenomas in the colon without AI assistance, according to a paper published by Budzyń et al in The Lancet Gastroenterology & Hepatology. Colonoscopy...
Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods
In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre–COVID-19 period, with no significant difference in recurrence or progression being observed. Study ...
Childhood Cancer Survivors and Long-Term Risks for Health Conditions: New Data
Some survivors of childhood cancers face a continued elevated risk of premature mortality, new cancers, chronic conditions, and other adverse health conditions as they grow older, according to new findings published in the Journal of Clinical Oncology. An increased risk for cancer and other...
Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach
In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from monotherapy with the PD-1 inhibitor pembrolizumab to platinum doublet chemotherapy plus...
Genomics-Guided Tool to Inform Treatment of Advanced Kidney Cancers
Results from a recent study may help to explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers create a first-of-its-kind tool to guide treatment decisions for patients with advanced kidney cancers. The collaborative work ...
Case 1: Role of ASCT in the Era of Quadruplet Induction and T-Cell–Redirected Therapies
This is Part 1 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with newly...
Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD)–activating mutations, as...
Survival in Older Patients With Cancer and Diabetes: GLP-1 RAs vs Other Glucose-Lowering Drugs
A retrospective cohort study published in JAMA Network Open found glucagon-like peptide-1 (GLP-1) receptor agonists to be associated with lower all-cause mortality than dipeptidyl peptidase-4 (DPP-4) inhibitors, with no significant difference from sodium-glucose cotransporter-2 (SGLT-2) inhibitors, ...
Smoking Cessation in Cancer Care: Challenges and Opportunities
Based on the results of a cohort study reported in JAMA Network Open, smoking worsened both cancer symptom burden and severity. However, Rieth et al noted that oncologic surgery may present a unique teachable moment for smoking cessation, as patients appeared to be highly motivated to quit. The...
Genetic Testing May Reduce Chemotherapy Side Effects for Patients With GI Cancers
For patients with gastrointestinal (GI) cancers, chemotherapy can sometimes cause severe, even life-threatening side effects in those who carry certain genetic variants that may impact how their bodies process the drugs used to treat their disease. Testing for variants in two genes before starting...
Novel Single-Cell Sequencing Blood Test for Multiple Myeloma
Researchers at Dana-Farber Cancer Institute have developed a blood test that may alter the diagnosis and monitoring of multiple myeloma and its precursor conditions. The new method, known as SWIFT-seq, uses single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a...
Real-World Study Highlights Gaps in Hypomethylating Agent Treatment for MDS
Researchers have identified age-, sex-, and race-related disparities around treatment with hypomethylating agents for patients with myelodysplastic syndromes in the United States. The receipt of hypomethylating agents was found to favor younger, male, White patients, according to findings published ...
RCC: Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes
Genetic testing may be the only way to differentiate between common and more rare subtypes of renal cell carcinoma (RCC) to prevent misdiagnoses, according to the results of a study published in Human Pathology. Mucinous tubular and spindle cell carcinoma (MTSCC) was found to share many...
Advancing Geriatric Oncology: Where We Have Been and Where We Are Going
The aging population is rapidly growing, with the number of older adults rising steadily each year. In the 1980s, experts predicted a rise in the number of older patients with cancer, yet we were unprepared. The shortage of oncologists, along with many experienced clinicians retiring early, has...
Perceived Dermatologic Side Effects of Cancer Treatment: Pilot Survey Findings
A recent study published by Menta et al in the Journal of Drugs in Dermatology found that many people misunderstand how common skin, hair, and nail side effects are during cancer treatment—and those fears may lead some to avoid or delay care. Conducted by researchers at the George Washington...
Pediatric Gliomas: Early Research on Targeted Therapies
A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most common type of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and these gliomas may be sensitive to...
Nivolumab Plus Ipilimumab in mCRPC With an Immunogenic Signature
In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signature–positive metastatic castration-resistant prostate cancer (mCRPC). Study Details The multicenter...
Ayurveda in Cancer Care
Guest Editor’s Note: Ayurveda, the traditional medical system that originated in India, focuses on improving overall well-being through self-care, diet, and herbal formulations. There is a growing patient interest in using Ayurveda for symptom control and to improve quality of life. In this...
Ultraprocessed Food Consumption May Be Linked to Increased Lung Cancer Risk
Greater consumption of ultraprocessed food is associated with an increased risk of developing either small cell or non–small cell lung cancer, according to findings published in Thorax. "Over the past 2 decades, the consumption of ultraprocessed food has significantly increased worldwide,...
Investigating the Mechanisms of Cardiovascular Adverse Events Linked to Certain Cancer Treatments
The true upside of the many advances in cancer treatment is clear. Approximately 18.6 million people in the United States have a history of cancer, and the number of cancer survivors is expected to exceed 22 million by the year 2035.1However, one downside affecting many of these individuals is...
Outcomes Associated With COVID-19 Infection in Patients With Cancer
As reported in JAMA Oncology by Rini et al, the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) has identified outcomes associated with COVID-19 in patients with cancer. Study Details Between May 2020 and February 2022, the study enrolled adult patients from sites participating ...
Prostate Cancer: One in Six Grade Group 1 Cases Linked to Higher-Risk Disease
Patients classified with "grade group 1" prostate cancer face a wide range of long-term outcomes, according to findings from a study published in JAMA Oncology. Investigators revealed that as many as one in six men with grade group 1 prostate cancers have intermediate- or high-risk disease when...
Immune Checkpoint Inhibitors, Cardiovascular Health, and a Potentially Protective Biomarker
New research out of Spain has shown that patients with cancer who had lower levels of the biomarker CD69 (receptor on T cells) before starting treatment with immune checkpoint inhibitors (ICIs) had a more negative immune response and were at higher risk of cardiovascular damage and myocarditis.1...
Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma
The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could reduce recurrence after definitive local therapy for patients who had high-risk features....
Does Preexisting Depression Impact Prostate Cancer Survival?
Based on the results of an analysis reported in JAMA Network Open by Zhang et al, preexisting depression is associated with an increased risk of mortality from prostate cancer. The investigators commented, “Approximately one in six patients with prostate cancer experience major depression, a...
Perioperative Pembrolizumab Plus Surgery and Risk-Adapted Standard Adjuvant Therapy Shows Benefit in Locally Advanced Head and Neck Cancer
Earlier this year, the first interim analysis of the phase III KEYNOTE-689 trial showed that the use of the PD-1 inhibitor pembrolizumab as part of a perioperative treatment regimen with standard-of-care surgery plus adjuvant radiotherapy (with or without cisplatin alone) improved event-free...
Cannabis Use Disorder and Risk of Oral Cancer
Cannabis use disorder was associated with at least a threefold increase in the risk for developing oral cancer over 5 years compared with those without cannabis use disorder, according to findings from a multicenter clinical cohort analysis published in Preventive Medicine Reports. “Cannabis smoke ...
FIGO Releases Best Practice Advice on Cancer During Pregnancy
The International Federation of Gynecology and Obstetrics (FIGO) has released a best practice guideline addressing cancer in pregnancy, a condition with limited data and complex diagnostic challenges. This new guidance—published by Nanda et al in the International Journal of Gynecology &...
Study Shows Increased Prescribing After Accelerated vs Regular Approval of Cancer Drugs
A cross-sectional study of cancer drug indications granted accelerated approval, which was published in JAMA Network Open, found that prescribing increased more after accelerated approval than after conversion to regular approval. Parikh et al also noted that off-label prescribing after accelerated ...
LLM Trained on Somatic Mutations Shows Prognostic and Predictive Utility
Large language models (LLMs) can be trained to understand how each patient’s somatic mutations impact their cancer prognosis and possible response to therapy, according to a presentation at the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning. John-William...
Acute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the impact of the prognostic marker RUNX1::RUX1T1 fusion on the diagnosis and treatment of...
AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis
A U.S. Food and Drug Administration (FDA)–cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective evaluation of screening digital breast tomosynthesis (DBT), findings published in Radiology showed. The...
Three in Five Liver Cancer Cases May Be Due to Preventable Risk Factors, The Lancet Commission Finds
Globally, three in five liver cancer cases may be due to preventable risk factors, and obesity-linked cases of the disease are on the rise, according to findings from The Lancet Commission on hepatocellular carcinoma. The majority of liver cancer cases could be prevented by reducing levels of viral ...
Similar Efficacy, Improved Safety Achieved Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Cancer
The PD-1 inhibitor toripalimab in combination with an induction chemoradiotherapy regimen free of concurrent cisplatin demonstrated noninferior efficacy and superior safety compared with the same regimen plus concurrent cisplatin in patients with high-risk, locoregionally advanced nasopharyngeal...
Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC
In a 4-year follow-up of the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Zhou et al examined the survival benefit of adding the PD-L1 inhibitor sugemalimab to first-line platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC) with no...
ACS Study Finds Firefighters Face Increased Cancer Risk and Mortality, Especially for Skin and Kidney Cancers
According to the International Association of Fire & Rescue Services, there are more than 15 million firefighters protecting the inhabitants of 60 countries around the world. And while hazardous exposures from fires encountered by firefighters vary, potential risks include several known or...
Study Finds Racial and Economic Segregation May Impact Advanced-Stage Breast and Cervical Cancer Diagnoses
Despite advances in early cancer detection, racial and ethnic minority individuals seem to be more likely to have a late-stage diagnosis of cancers that have a recommended screening. A large study by the American Cancer Society that examined the association between neighborhood-level segregation...
STRIDE in Unresectable HCC: 5-Year Overall Survival Results From HIMALAYA
A recent exploratory analysis of the phase III HIMALAYA trial involving patients with unresectable hepatocellular carcinoma (HCC) has shown that 1 in 5 participants (19.6%) treated with the STRIDE regimen (single tremelimumab regular interval durvalumab) remained alive after 5 years of follow-up vs ...
